凯赛生物
(688065)
| 流通市值：263.80亿 | | | 总市值：326.17亿 |
| 流通股本：5.83亿 | | | 总股本：7.21亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 9,405,030,835.76 | 9,251,568,474.45 | 8,106,447,949.81 | 8,720,310,517.31 |
| 交易性金融资产 | 469,248 | 469,248 | 901,795,880.68 | 1,102,641,476.69 |
| 应收票据及应收账款 | 470,084,468.45 | 440,074,975.97 | 486,826,035.88 | 472,556,539.42 |
| 其中：应收票据 | 124,236,456.58 | 142,579,117.59 | 160,427,269.4 | 124,115,812.78 |
| 应收账款 | 345,848,011.87 | 297,495,858.38 | 326,398,766.48 | 348,440,726.64 |
| 应收款项融资 | 359,760,744.93 | 79,736,532.73 | 198,809,011.95 | 88,047,804.47 |
| 预付款项 | 82,503,448.03 | 78,779,918.59 | 121,383,568.55 | 108,577,399.82 |
| 其他应收款合计 | 5,545,558.32 | 7,772,423.5 | 6,323,266.39 | 4,659,625.03 |
| 存货 | 1,401,033,381.24 | 1,440,116,190.87 | 1,285,422,426.91 | 1,162,077,938.27 |
| 其他流动资产 | 542,086,708.74 | 432,875,681.27 | 384,259,152.19 | 352,780,288.27 |
| 流动资产合计 | 12,266,514,393.47 | 11,731,393,445.38 | 11,491,267,292.36 | 12,011,651,589.28 |
| 非流动资产: | | | | |
| 长期股权投资 | 199,914,262.41 | 203,674,594.05 | 151,236,089.55 | 153,249,731.62 |
| 固定资产 | 3,590,822,784.4 | 3,654,120,244.24 | 3,676,026,559.34 | 3,759,761,042.1 |
| 在建工程 | 6,742,391,203.81 | 6,600,655,073.42 | 6,412,037,077.97 | 6,146,630,850.8 |
| 无形资产 | 723,693,464.13 | 728,504,420.69 | 685,341,473.61 | 690,142,932.51 |
| 长期待摊费用 | 6,075,520.66 | 3,207,339.9 | 3,814,709.85 | 4,585,548.74 |
| 递延所得税资产 | 282,304,459.9 | 278,118,201.53 | 254,149,077.06 | 239,331,623.18 |
| 其他非流动资产 | 745,486,636.62 | 682,609,653.85 | 771,235,618.97 | 815,829,349.52 |
| 非流动资产合计 | 12,290,688,331.93 | 12,150,889,527.68 | 11,953,840,606.35 | 11,809,531,078.47 |
| 资产总计 | 24,557,202,725.4 | 23,882,282,973.06 | 23,445,107,898.71 | 23,821,182,667.75 |
| 流动负债: | | | | |
| 短期借款 | 761,509,799.51 | 301,223,184.45 | 71,754,307.62 | 50,384,874.4 |
| 应付票据及应付账款 | 1,347,006,834.71 | 1,403,724,038.58 | 1,395,355,925.7 | 1,350,425,010.24 |
| 应付账款 | 1,347,006,834.71 | 1,403,724,038.58 | 1,395,355,925.7 | 1,350,425,010.24 |
| 预收款项 | 1,007,734.87 | 2,663,954.9 | 4,030,939.45 | - |
| 合同负债 | 59,404,046.4 | 30,608,805.69 | 26,597,789.15 | 36,242,732.82 |
| 应付职工薪酬 | 9,533,697.83 | 24,463,952.37 | 18,547,290.12 | 13,109,665.17 |
| 应交税费 | 40,698,051.84 | 38,994,006.53 | 47,037,407.28 | 45,748,095.88 |
| 其他应付款合计 | 146,669,104.01 | 188,158,209.08 | 79,469,328.11 | 363,608,801.11 |
| 应付股利 | 831,600 | 831,600 | 831,600 | 288,411,051.6 |
| 一年内到期的非流动负债 | 28,126,625.74 | 12,809,312.2 | 9,718,253.72 | 11,911,200.98 |
| 其他流动负债 | 7,722,526.03 | 3,853,606.34 | 3,457,712.59 | 4,711,555.27 |
| 流动负债合计 | 2,401,678,420.94 | 2,006,499,070.14 | 1,655,968,953.74 | 1,876,141,935.87 |
| 非流动负债: | | | | |
| 长期借款 | 303,435,314.68 | 188,963,845.31 | 197,754,693.92 | 492,684,716.92 |
| 递延收益 | 366,841,138.62 | 371,976,134.22 | 374,249,053.44 | 377,240,955.59 |
| 递延所得税负债 | - | - | 198,994.9 | 325,834.31 |
| 非流动负债合计 | 670,276,453.3 | 560,939,979.53 | 572,202,742.26 | 870,251,506.82 |
| 负债合计 | 3,071,954,874.24 | 2,567,439,049.67 | 2,228,171,696 | 2,746,393,442.69 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 721,289,794 | 721,289,794 | 721,289,794 | 721,289,794 |
| 资本公积 | 14,250,396,810.49 | 14,245,681,528.54 | 14,301,719,605.24 | 14,300,235,186.22 |
| 减:库存股 | 109,056,939.1 | 109,056,939.1 | 155,630,224.62 | 155,630,224.62 |
| 其他综合收益 | 3,095,913.2 | 2,936,809.38 | 2,655,899.27 | 2,200,999.71 |
| 专项储备 | 21,262,940.62 | 20,235,258.64 | 19,286,267.12 | 17,856,739.44 |
| 盈余公积 | 240,367,413.62 | 240,367,413.62 | 238,968,963.77 | 238,968,963.77 |
| 未分配利润 | 2,744,017,373.63 | 2,578,300,500.66 | 2,469,652,744.13 | 2,327,645,963.86 |
| 归属于母公司股东权益合计 | 17,871,373,306.46 | 17,699,754,365.74 | 17,597,943,048.91 | 17,452,567,422.38 |
| 少数股东权益 | 3,613,874,544.7 | 3,615,089,557.65 | 3,618,993,153.8 | 3,622,221,802.68 |
| 股东权益合计 | 21,485,247,851.16 | 21,314,843,923.39 | 21,216,936,202.71 | 21,074,789,225.06 |
| 负债和股东权益合计 | 24,557,202,725.4 | 23,882,282,973.06 | 23,445,107,898.71 | 23,821,182,667.75 |
| 公告日期 | 2026-04-30 | 2026-04-24 | 2025-10-31 | 2025-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |